These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2956047)

  • 1. The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus.
    Campbell IW; Duncan C; Patton NW; Broadhead T; Tucker GT; Woods HF
    Diabet Med; 1987; 4(4):337-41. PubMed ID: 2956047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
    BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
    Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G
    Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
    DeFronzo RA; Barzilai N; Simonson DC
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes.
    Santos RF; Nomizo R; Wajhenberg BL; Reaven GM; Azhar S
    Diabete Metab; 1995 Oct; 21(4):274-80. PubMed ID: 8529763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
    Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
    Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
    Giugliano D; Quatraro A; Consoli G; Minei A; Ceriello A; De Rosa N; D'Onofrio F
    Eur J Clin Pharmacol; 1993; 44(2):107-12. PubMed ID: 8453955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    Cusi K; Consoli A; DeFronzo RA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment.
    Calle-Pascual AL; Garcia-Honduvilla J; Martin-Alvarez PJ; Vara E; Calle JR; Munguira ME; Marañes JP
    Diabete Metab; 1995 Oct; 21(4):256-60. PubMed ID: 8529760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients.
    Hermann LS; Kalén J; Katzman P; Lager I; Nilsson A; Norrhamn O; Sartor G; Ugander L
    Diabetes Obes Metab; 2001 Dec; 3(6):428-34. PubMed ID: 11903415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.